No open-market selling at Oncotelic Therapeutics, Inc. in the past year, which is unusual. Instead two executives and directors bought into about $38,000 worth of OTLC.
Trieu Vuong (CEO) made the biggest buy, worth around $9,600. That includes C-suite money, which tends to get the most attention.
2 quarters in a row of net buying by insiders. Insiders bought in 4 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Trieu Vuong | CEO | Buy | 240,000 | $0.04 | $10K | SEC |
| Jun 24, 2026 | Trieu Vuong | CEO | Buy | 115,000 | $0.05 | $6K | SEC |
| Jun 24, 2026 | Trieu Vuong | CEO | Buy | 65,000 | $0.05 | $3K | SEC |
| Jun 24, 2026 | Trieu Vuong | CEO | Buy | 75,000 | $0.05 | $4K | SEC |
| Jun 22, 2026 | Shah Amit B. | CFO | Buy | 20,000 | $0.05 | $1K | SEC |
| Jun 17, 2026 | Trieu Vuong | CEO | Buy | 96,000 | $0.05 | $5K | SEC |
| Jun 17, 2026 | Trieu Vuong | CEO | Buy | 239,759 | $0.04 | $10K | SEC |
| Jul 10, 2025 | Trieu Vuong | CEO | Buy | 94,736 | $0.01 | $947 | SEC |
| Jul 10, 2025 | Trieu Vuong | CEO | Buy | 1 | $0.01 | $0 | SEC |
| Jul 10, 2025 | Trieu Vuong | CEO | Buy | 104,000 | $0.01 | $1K | SEC |
| Jan 31, 2025 | Trieu Vuong | CEO | Buy | 63,775 | $0.03 | $2K | SEC |
| Jan 31, 2025 | Trieu Vuong | CEO | Buy | 100,003 | $0.03 | $3K | SEC |
| Jan 31, 2025 | Trieu Vuong | CEO | Buy | 183,066 | $0.03 | $5K | SEC |
| Nov 26, 2024 | Trieu Vuong | CEO | Buy | 298,499 | $0.03 | $9K | SEC |
| Aug 27, 2024 | Trieu Vuong | CEO | Buy | 500,000 | $0.02 | $10K | SEC |
In the last 12 months Oncotelic Therapeutics, Inc. insiders made open-market purchases worth about $38,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in OTLC was filed on 2026-07-02.
No congressional trades in OTLC were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).